However, as 5-azacytidine treatment leads to DNA demethylation on a global scale rather than specific demethylation of the PDGFRA-CTCF site [27], Treatment with dasatinib as TKI may add a more targeted treatment option for IDH1-mut AML specifically. The gene discussed is IDH1; the disease is acute myeloid leukemia.